Horizon Pharma plc to Participate in Two Conferences in May
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 05/04/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that it will attend and present at the following conferences in May:
Presentation Date: Tuesday, May 12, 2015
Presentation Time: 4:20 p.m. PT (7:20 p.m. ET)
Presentation Date: Monday, May 18, 2015
Presentation Time: 1:00 p.m. ET
The presentations will be webcast live and may be accessed by visiting Horizon's website at . A replay of the webcast will be available for 10 business days.
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit .
John Thomas
Executive Vice President, Strategy and Investor Relations
Geoff Curtis
Group Vice President, Corporate Communications
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2015 - 11:00 Uhr
Sprache: Deutsch
News-ID 390404
Anzahl Zeichen: 0
contact information:
Town:
DUBLIN, IRELAND
Kategorie:
Diese Pressemitteilung wurde bisher 131 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Horizon Pharma plc to Participate in Two Conferences in May"
steht unter der journalistisch-redaktionellen Verantwortung von
Horizon Pharma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
